Form 4: Aquestive Therapeutics Director, Gregory B Brown, Acquires Stock Options

Director Gregory B Brown acquired 38,000 stock options in Aquestive Therapeutics, Inc.

Summary

• Gregory B Brown, a director of Aquestive Therapeutics, Inc. (AQST), reported a transaction involving derivative securities.
• On June 20, 2024, Brown acquired 38,000 stock options with an exercise price of $2.50.
• These options vest on June 20, 2025, contingent upon Brown's continued service with the company.
• The options expire on June 20, 2034.
• Following the transaction, Brown directly owns 38,000 derivative securities.
• Brown also directly owns 75,085 shares of Aquestive Therapeutics common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants. The director's acquisition could be interpreted as a slightly positive signal.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Insider transactions are routinely monitored to gauge executive sentiment and potential future performance of a company. Option grants are a common form of executive compensation in the pharmaceutical industry.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates